05:47 AM EDT, 03/28/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Wednesday the China National Medical Products Administration has accepted for review its supplemental new drug application for savolitinib as a treatment for adult patients with locally advanced or metastatic non-small cell lung cancer.

If it is approved, the new label indication for savolitinib will be expanded to include treatment-naive patients in China, the company said.